Skip to main content
NCBI home page
Scientific Reports logoLink to Scientific Reports
. 2016 Jul 14;6:29849. doi: 10.1038/srep29849

Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach

Lei Chen 1,2,*, Tao Huang 3,*, Yu-Hang Zhang 3,*, Yang Jiang 4,a, Mingyue Zheng 5,b, Yu-Dong Cai 1,c
PMCID: PMC4944139  PMID: 27412431

Abstract

Tumors are formed by the abnormal proliferation of somatic cells with disordered growth regulation under the influence of tumorigenic factors. Recently, the theory of “cancer drivers” connects tumor initiation with several specific mutations in the so-called cancer driver genes. According to the differentiation of four basic levels between tumor and adjacent normal tissues, the cancer drivers can be divided into the following: (1) Methylation level, (2) microRNA level, (3) mutation level, and (4) mRNA level. In this study, a computational method is proposed to identify novel lung adenocarcinoma drivers based on dysfunctional genes on the methylation, microRNA, mutation and mRNA levels. First, a large network was constructed using protein-protein interactions. Next, we searched all of the shortest paths connecting dysfunctional genes on different levels and extracted new candidate genes lying on these paths. Finally, the obtained candidate genes were filtered by a permutation test and an additional strict selection procedure involving a betweenness ratio and an interaction score. Several candidate genes remained, which are deemed to be related to two different levels of cancer. The analyses confirmed our assertions that some have the potential to contribute to the tumorigenesis process on multiple levels.

Tumors are defined as new creatures formed by the abnormal proliferation of somatic cells with disordered growth regulation under the influence of tumorigenic factors1. Around the world, tumors have been reported to be the second killer of human health, ranked only behind cardiovascular disease. However, it is still not clear how tumor tissues initiate and invade during the precancerous lesion stage2. Specific genetic alterations have been detected in tumor cells of different types. Some well-known genes, such as p53, K-Ras, etc., have been reported in various tumor types, which have been regarded as genomic markers for the given tumors and may be the original mutation related to tumor initiation and progression3,4.

In 2012, the theory of “cancer drivers” was first presented at the RAOF (Round Asia Oncology Forum), which connects tumor initiation with several specific mutations in the so-called cancer driver genes5. Such theory attributes tumor initiation to several original specific genomic alterations, which sequentially induce metabolic and functional disorders in somatic cells. As we know, based on the differentiation of four basic levels between the tumor and adjacent normal tissues, we can divide cancer driver genes into four clusters: (1) Methylated CpG site genes, (2) microRNA target genes, (3) somatic mutation genes, and (4) mRNA genes.

First, the level of methylation of driver genes may change during tumor initiation. Generally, the methylation and demethylation of peculiar regions in chromosomes reflects the regulation of gene expression on the transcriptional level6. The demethylation of oncogenes and/or the methylation of tumor suppressors may induce the proliferation and genomic instability of tumor cells7. Such processes may be the driving procedures of tumor initiation and progression. In addition to methylation and demethylation, another level cancer driver genes contribute to is associated with microRNA expression8. microRNA is a small non-coding RNA molecule that contributes to post-transcriptional regulation by RNA silencing9. During tumor initiation and progression, the specific microRNA expression level changes and may further regulate its functional target genes10. Such microRNA target genes are regulated differently in the tumor versus normal tissues. Thus, the level of functional microRNAs may also reveal several cancer driver genes. Genomic instability is another basic characteristic of tumor cells. As a result of that, mutations exist extensively in malignant cells. Therefore, the third level for cancer driver genes to initiate tumors is mutations. Some cancer driver genes, such as p53 and K-Ras, include specific mutations which contribute to the structural and functional changes of their protein products and may further induce tumor initiation and progression11. Mutations not only occur in the exons of driver genes but in their regulatory sequences as well, such as promoters, enhancers, etc.12,13. These mutations may not alter the structures or functions of target proteins which are encoded by driver genes but may strongly improve or reduce the quantity of mRNAs and proteins14. Apart from that, some unique abnormal regulatory factors with mutations may also contribute to the regulation of cancer genes at the transcription and/or translation levels15.

Lung adenocarcinoma is a typical subtype of lung cancer that is highly related to specific genetic background16. As a crucial threat to human health, however, most studies on lung adenocarcinoma drivers are restricted to a single level (one of the four clusters as we have mentioned above) and the core driver factors that contribute to the initiation and progression of lung adenocarcinoma have not been fully revealed. In these studies, most progressions of lung adenocarcinoma associated drivers mainly concentrate to the mutations and copy number variations (CNVs) of particular oncogenes17,18. For example, it has been widely confirmed by in vitro and in vivo experiments that specific mutations of EGFR and KRAS may exactly drive the initiation and progression of lung adenocarcinoma, implying the key role of certain drivers for the tumorigenesis of lung adenocarcinoma19,20. Apart from that, on another level, a specific microRNA associated mutation (target site on KRT81) has also been reported to be associated with lung adenocarcinoma21. As stated above, the original specific genomic alterations may contribute to tumor initiation in multiple levels, implying the analysis of specific variant should be extended to multi-omics. However, few multi-level analysis (such as the combination of mutations and copy number variants) of lung adenocarcinoma drivers have been presented and reported. For the first time, based on TCGA database, our study concentrate on all the four levels of drivers as we have mentioned above and try to fill the gap of this research field.

In this study, we investigated the specific driver factors of lung adenocarcinoma on four functional levels based on the gene expression, microRNA expression, DNA methylation and somatic mutation data of lung adenocarcinoma tissues and normal control samples from TCGA (The Cancer Genome Atlas)22. We first sought to search all the shortest paths (SP) connecting dysfunctional genes on different levels in a large network constructed by protein-protein interactions (PPI) and to identify new candidate cancer driver genes on these paths. Then, these genes were filtered by a permutation test and a strict selection procedure. The final obtained candidate genes were deemed to be related to two different levels, i.e., they can drive tumorigenesis on two levels. Furthermore, some candidate genes may occur more than once, meaning that they can drive tumorigenesis on multiple levels. The more levels a gene can drive tumor initiation, the more significant the gene may be.

Materials and Methods

Dataset

We downloaded the gene expression, microRNA expression, DNA methylation and somatic mutation data of lung adenocarcinoma tissues and normal control samples from TCGA (https://tcga-data.nci.nih.gov/docs/publications/luad_2014/)22.

The expression level of 20,531 genes in 230 tumor samples and 43 normal samples was measured with RNA-Seq and transformed into the log2 scale. The expression level of 1,046 microRNAs in 181 tumor samples and 32 normal samples was measured with microRNA-Seq and also transformed onto the log2 scale. The DNA methylation level of 485,577 CpG sites in 181 tumor samples and 21 normal samples was measured using the Infinium HumanMethylation450 BeadChip array. The somatic mutation data of 14,989 genes in 230 tumor samples were called with MuTect23.

Identification of the differentially expressed mRNA genes, microRNAs, methylated CpG sites and somatic mutation genes

We used the SAM (Significance Analysis of Microarrays) method24 to detect differentially expressed genes, microRNAs, and the methylated CpG sites. There were 1,373 differentially expressed mRNA genes, 42 microRNAs and 295 methylated CpG sites with a SAM FDR (False Discovery Rate) less than 0.01 and a fold change greater than 5. The 42 microRNAs regulated 825 target genes based on at least three out of six microRNA-target databases, including miRBase25 (http://microrna.sanger.ac.uk/targets/v5/), TargetScan26 (http://www.targetscan.org/), miRanda27 (http://www.microrna.org/microrna/), TarBase28 (http://diana.cslab.ece.ntua.gr/tarbase/), mirTarget229 (http://mirdb.org/miRDB/download.html), and PicTar30 (http://pictar.mdc-berlin.de/). The 295 differentially expressed methylated CpG sites were annotated to 153 genes based on their chromosome locations from TCGA. The 197 somatic mutation genes with mutation frequencies greater than 10% were selected.

As a result, 153 methylated CpG site genes, 825 microRNA target genes, 197 somatic mutation genes, and 1,373 differentially expressed mRNA genes were considered seed genes and comprised the gene sets G1, G2, G3 and G4, respectively. The symbols of these genes are provided in the Supplementary Material I.

Network construction

The constructed network was built according to the PPI information retrieved from STRING (Search Tool for the Retrieval of Interacting Genes/Proteins, http://www.string-db.org/, Version 9.1)31,32. The obtained file, ‘protein.links.v9.1.txt.gz’, contained large numbers of PPIs involving 1,133 organisms. In total, 2,425,314 human PPIs were extracted from this file by selecting lines starting with ‘9606.’. PPIs reported in STRING are obtained by the following sources: (1) genomic context, (2) high-throughput experiments, (3) (conserved) co-expression, and (4) previous knowledge. Thus, they can widely measure the associations between proteins and have been used to deal with several protein related problems33,34,35,36,37,38,39,40. For each of the 2,425,314 human PPIs, there are two proteins represented by Ensembl IDs and a score, indicating the strength of the interaction ranging between 150 and 999. Proteins in an interaction with a high score have strong associations. The constructed network took all the proteins occurring in 2,425,314 human PPIs, totaling 20,770 proteins, as nodes, and two nodes were connected by an edge if and only if the corresponding proteins could comprise an interaction. Clearly, each edge represented a human PPI. To indicate the score of each interaction, each edge should be assigned a weight. Because the range of the interaction score is between 150 and 999, i.e., the maximum value of interaction score is 999, and a model using the shortest path algorithm as a basic algorithm requires edges assigned low weights indicate strong associations between corresponding nodes, the weight of each edge in the constructed network was defined as 1,000 minus the interaction score of the corresponding interaction.

SP method for searching new candidate cancer drivers

It has been reported in some studies that two proteins in a PPI may share similar functions33,35,38,41,42,43. By further considering the interaction score, two proteins in a PPI with a high score are more likely to share similar functions. This can be further induced by the fact that if p1, p2,…,ps is a series of proteins such that pi and pi+1 can comprise a PPI with a high score (the corresponding edge in the network was assigned a low weight), and p1 and ps are two proteins encoded by dysfunctional genes, then p2,…,ps−1 may also be encoded by dysfunctional genes. By mapping p1, p2,…,ps to the network constructed in Section “Network construction”, the corresponding nodes can comprise the shortest path by the construction of the network. Because dysfunctional genes can be divided into four levels, comprising of four sets of seed genes denoted by G1, G2, G3 and G4, we searched candidate genes by pairing Gi and Gj (i  ≠ j) to identify new genes that can drive tumorigenesis on two levels. Thus, for any Gi and Gj (i  ≠ j), we searched all of the shortest paths connecting genes in Gi and Gj by Dijkstra’s algorithm44. Accordingly, we obtained six sets of the shortest paths. For each set, we extracted genes that occurred in at least one path as the candidate genes. Furthermore to distinguish them, a measurement, namely betweenness45, was conducted for each candidate gene, which is defined as the number of paths containing the gene. Betweenness is a measure of centrality of a vertex within a graph which counts the number of times a node acts as a bridge in the shortest path between two other nodes, which in this study can be used to judge whether the candidate genes can drive tumor initiation on two levels46. For convenience, the set consisting of candidate genes for Gi and Gj is denoted by Inline graphic.

Permutation test

For Gi and Gj (i ≠ j), we can obtain a set of candidate genes, making up the gene set Inline graphic, by the method described in Section “SP method for searching new candidate cancer drivers”. However, not all of them have the potential to become novel driver genes. False positives are inevitable. Among them, some are produced by the construction of the network. Taking this into consideration, we randomly produced two groups of gene sets; each group contained 1,000 gene sets, denoted by Inline graphic and Inline graphic. Inline graphic is the same size as Gi , while Inline graphic is the same size as Gj . For Inline graphic and Inline graphic (k = 1,2, …, 1000), all the shortest paths connecting one gene in Inline graphic and one gene in Inline graphic were searched in the constructed network. We counted the betweenness of the candidate genes in Inline graphic based on these paths. Thus, each candidate gene had one betweenness on Gi and Gj and 1,000 betweenness on Inline graphic and Inline graphic (k = 1,2, …,1000). Another measurement, namely permutation FDR, was computed for each candidate gene, which is defined as the ratio of the 1,000 betweenness on Inline graphicand Inline graphic (k = 1,2, …,1000) that are larger than the betweenness on Gi and Gj. It can be seen that a candidate gene with a high permutation FDR is more likely to be a false positive produced by the construction of the network and should be excluded. Thus, candidate genes with a permutation FDR larger than or equal to 0.05 were discarded. The remaining candidate genes, making up the gene set Inline graphic, were further evaluated by the method in the following section.

Further selection using betweenness and PPI

For Gi and Gj (i ≠ j), some candidate genes remained after executing the permutation test. However, some of them may have strong associations with cancer, while others have weak associations. To reflect this fact, we proposed some rules in this section and selected the important candidate genes based on these rules.

It has been elaborated that the betweenness of a candidate gene is the number of paths connecting genes in Gi and in Gj including the candidate gene. Clearly, a candidate gene with high betweenness suggests it has strong associations with genes in Gi and Gj, thereby having a high likelihood of being a novel cancer driver gene. To build a uniform rule, we must also consider the sizes of Gi and Gj because a candidate gene with a small betweenness for small Gi and Gj is not always less important than another candidate gene with a large betweenness for large Gi and Gj. Thus, we set a betweenness ratio R(g) to measure the importance of a candidate gene g based on its betweenness and sizes of Gi and Gj, which is defined as

graphic file with name srep29849-m17.jpg

It can be seen that a high betweenness ratio of a candidate gene means that the majority of the shortest paths connecting genes in Gi and in Gj contains the candidate gene. We set a threshold of 0.01 for the betweenness ratio to select important candidate genes.

Another rule was built based on the PPIs and their interaction scores. It has been reported that two proteins in a PPI with a high score are more likely to share similar functions33,47,48. Thus, for a candidate gene g, if g and genes in Gi and Gj can comprise PPIs with high interaction scores, g has strong associations with genes in Gi and Gj. Thus, we computed the following value, namely the min-max interaction score:

graphic file with name srep29849-m18.jpg

Similarly, a candidate gene with a high min-max interaction score implies that it has strong associations with at least one gene in Gi and at least one gene in Gj, indicating that it has a high linkage with cancer. Similar to the proportion mentioned in the paragraph above, we can also set a threshold of 400 for the min-max interaction score to select important candidate genes.

For the gene sets Gi and Gj, genes in Inline graphic were filtered by the above two rules. The remaining genes constituted the set Inline graphic, which were deemed to be significant for two levels.

Results

In this study, we proposed a computational method to identify candidate cancer driver genes that can drive tumor initiation on multiple levels. The flowchart of our method is shown in Fig. 1. The results of our method are described in the following sections.

Figure 1. Flowchart of our method.

Figure 1

Open in a new tab

(A) Four gene sets consisting of dysfunctional genes on four levels; (B) SP method to search candidates in a network. Yellow nodes represent dysfunctional genes on different levels, and the dashed lines represent the shortest path connecting a and i, e and h are selected; (C) Six candidate gene sets obtained by the SP method; (D) Permutation test to filter some false positives. Two randomly produced sets {d, f} and {c, g} were shown in the network (highlighted in red and green), in detail, red nodes d and c replace yellow node a, while green nodes g and f replace yellow node i, dotted lines represent the shortest path connecting d and f, dashed-dotted lines represent the shortest path connecting c and g, and e (highlighted in pink) is removed by the permutation test; (E) Six candidate gene sets filtered by the permutation test; (F) Six candidate gene sets filtered by further selection using betweenness and PPI.

Results of the SP method

As mentioned in Section “Identification of the differentially expressed mRNA genes, microRNAs, methylated CpG sites and somatic mutation genes”, we employed four gene sets G1, G2, G3 and G4 with different expression levels for cancer. For each pair, e.g., Gi and Gj (i ≠ j), we searched all the shortest paths connecting any gene in Gi with any gene in Gj in a network constructed in Section “Network construction” and extracted genes on these paths. The obtained six sets of candidate genes, Inline graphic, are provided in the Supplementary Material II. The numbers of genes in these sets are listed in column 2 of Table 1. It can be seen that many candidate genes were included in each set, meaning that further filtering was necessary. Furthermore, the betweenness of each candidate gene in Inline graphic was calculated and also provided in the Supplementary Material II.

Table 1. Number of candidate genes obtained by the SP method and filtered by the permutation test and further selection.

Pair of gene sets Number of candidate genes obtained by SP method (Inline graphic) Number of candidate genes filtered by permutation test (Inline graphic) Number of candidate genes filtered by further selection using betweenness and PPI (Inline graphic)
G1 and G2 1355 310 27
G1 and G3 723 242 42
G1 and G4 1606 455 39
G2 and G3 1402 357 45
G2 and G4 2515 485 33
G3 and G4 1705 431 56
Open in a new tab

G1: A set containing 153 methylated CpG site genes; G2: A set containing 825 microRNA target genes; G3: A set containing 197 somatic mutation genes; G4: A set containing 1,373 mRNA genes.

Results of the permutation test

To control for the false positives produced by the construction of the network in each candidate set Inline graphic, a permutation test was adopted. A permutation FDR was calculated for each candidate gene in Inline graphic, which is also listed in the Supplementary Material II. By setting a threshold of 0.05 for the permutation FDR, we extracted a candidate gene subset Inline graphic from Inline graphic. The detailed genes in the six gene sets Inline graphic are provided in the Supplementary Material III, and the numbers of genes in these sets are listed in column 3 of Table 1, from which we can see that the number of candidate genes decreased significantly and became close to the reality.

Results of further selection

To select the core genes in Inline graphic, we calculated the betweenness ratio (cf. Equation 1) and the min-max interaction score (cf. Equation 2) for each candidate gene using a threshold of 0.01 for the betweenness ratio and a threshold of 400 for the min-max interaction score. These two measurements of each candidate gene are provided in the Supplementary Material III, and the remaining genes are listed in the Supplementary Material IV. The number of genes in the gene sets Inline graphic is listed in column 4 of Table 1. Compared to the number of candidate genes listed in column 3 of Table 1, the candidate genes were again decreased significantly. It is believed that these candidate genes have few false positives and have strong associations with cancer. Some of them are discussed in the following section.

Discussion

Analysis of candidate genes of two levels

Cancer driver genes as we have mentioned above have been widely reported to be the driving force for the tumorigenesis. According to our method, we obtained various genes that contribute to the initiation and progression of lung adenocarcinoma on at least two levels of the four basic driver levels (methylation, mutations, microRNA expression and expression/mRNA). The important candidates involving any two driver levels are listed in Tables 2, 3, 4, 5, 6, 7. Here, we only provide the brief analyses, the detailed analyses are provided in Supplementary Material V.

Table 2. Important candidate genes in Inline graphic (based on methylated CpG site genes and microRNA target genes) identified by our method.

Ensembl ID Gene symbol Description Betweenness Permutation FDR Betweenness ratio Min-Max interaction score
ENSP00000403005 EFNA4 Ephrin-A4 1597 <0.001 0.014897 679
ENSP00000337088 MEN1 Multiple Endocrine Neoplasia I 7269 <0.001 0.067808 719
ENSP00000352262 MLL Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) 7342 <0.001 0.068489 988
ENSP00000405890 PBX1 Pre-B-Cell Leukemia Homeobox 1 2529 <0.001 0.023591 822
ENSP00000297261 SHH Sonic Hedgehog 2800 0.001 0.026119 986
ENSP00000262965 TCF3 Transcription Factor 3 2651 <0.001 0.024729 985
Open in a new tab

Table 3. Important candidate genes in Inline graphic (based on methylated CpG site genes and somatic mutation genes) identified by our method.

Ensembl ID Gene symbol Description Betweenness Permutation FDR Betweenness ratio Min-Max interaction score
ENSP00000344456 CTNNB1 Catenin (Cadherin-Associated Protein), Beta 1, 88kDa 3240 <0.001 0.126592 996
ENSP00000287934 FZD1 Frizzled Class Receptor 1 382 0.002 0.014925 813
ENSP00000337088 MEN1 Multiple Endocrine Neoplasia I 1567 <0.001 0.061225 719
ENSP00000352262 MLL Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) 1581 <0.001 0.061772 571
ENSP00000297261 SHH Sonic Hedgehog 706 <0.001 0.027585 985
ENSP00000262965 TCF3 Transcription Factor 3 571 0.002 0.02231 420
Open in a new tab

Table 4. Important candidate genes in Inline graphic (based on methylated CpG site genes and mRNA genes) identified by our method.

Ensembl ID Gene symbol Description Betweenness Permutation FDR Betweenness ratio Min-Max interaction score
ENSP00000337088 MEN1 Multiple Endocrine Neoplasia I 9748 <0.001 0.059972 719
ENSP00000297261 SHH Sonic Hedgehog 4782 <0.001 0.02942 995
ENSP00000262965 TCF3 Transcription Factor 3 4274 <0.001 0.026295 987
Open in a new tab

Table 5. Important candidate genes in Inline graphic (based on microRNA target genes and somatic mutation genes) identified by our method.

Ensembl ID Gene symbol Description Betweenness Permutation FDR Betweenness ratio Min-Max interaction score
ENSP00000297268 COL1A2 Collagen, Type I, Alpha 2 2577 <0.001 0.016865 985
ENSP00000371138 FKBP1A FK506 Binding Protein 1A, 12kDa 3140 <0.001 0.02055 998
ENSP00000358525 NGF Nerve Growth Factor (Beta Polypeptide) 4923 <0.001 0.032219 943
ENSP00000401303 SHC1 SHC (Src Homology 2 Domain Containing) Transforming Protein 1 6291 <0.001 0.041171 999
ENSP00000348444 TTN Titin 3248 <0.001 0.021257 504
Open in a new tab

Table 6. Important candidate genes in Inline graphic (based on microRNA target genes and mRNA genes) identified by our method.

Ensembl ID Gene symbol Description Betweenness Permutation FDR Betweenness ratio Min-Max interaction score
ENSP00000263253 EP300 E1A Binding Protein P300 60273 <0.001 0.062112 995
ENSP00000339007 GRB2 Growth Factor Receptor-Bound Protein 2 48282 <0.001 0.049755 939
ENSP00000296585 ITGA2 Integrin, Alpha 2 (CD49B, Alpha 2 Subunit Of VLA-2 Receptor) 12251 0.002 0.012625 987
ENSP00000293379 ITGA5 Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide) 25513 0.004 0.026291 964
ENSP00000332353 PTCH1 Patched 1 17300 <0.001 0.017828 939
ENSP00000297261 SHH Sonic Hedgehog 10778 <0.001 0.011107 986
ENSP00000354720 SMC3 Structural Maintenance Of Chromosomes 3 10413 0.001 0.010731 986
Open in a new tab

Table 7. Important candidate genes in Inline graphic (based on somatic mutation genes and mRNA genes) identified by our method.

Ensembl ID Gene symbol Description Betweenness Permutation FDR Betweenness ratio Min-Max interaction score
ENSP00000242577 DYNLL1 Dynein, Light Chain, LC8-Type 1 6746 <0.001 0.029117 803
ENSP00000296585 ITGA2 Integrin, Alpha 2 (CD49B, Alpha 2 Subunit Of VLA-2 Receptor) 9109 <0.001 0.039317 959
ENSP00000293379 ITGA5 Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide) 10741 <0.001 0.046361 835
ENSP00000277541 NOTCH1 Notch 1 11069 <0.001 0.047776 948
ENSP00000228307 PXN Paxillin 3913 <0.001 0.016889 702
Open in a new tab

For the levels of methylation diversity and microRNA expression abundance, 27 genes were predicted to driver the lung adenocarcinoma in such two levels. Among them, six of them have the evidences to support the claim and are listed in Table 2. Interacting with specific microRNAs such as microRNA-142-3p, functional genes like TCF3, MEN1, MLL, EFNA4, PBX1, and SHH have all been confirmed to contribute to tumorigenesis via methylation alteration and microRNA regulation (The detailed analysis of the important candidates can be seen in Supplementary Material V). Take TCF3 as an example. The methylation alteration of TCF3 has been confirmed to contribute to the proliferation of A549 cells, a typical lung adenocarcinoma cell line in vitro experiments, implying that such gene may also contribute to the initiation and progression of lung adenocarcinoma on such level49. As for the microRNA level, the interactions between TCF3 and a group of microRNAs (miR-590, miR-17 and miR-18) has been confirmed, validating that TCF3 may also contribute to the initiation and progression of lung adenocarcinoma on such level50. For the methylation diversity and mutation differentiation, there are still several genes (such as TCF3, MLL, MEN1, SHH, CTNNB1 and FZD1, listed in Table 3) that have been reported to participate in the tumor associated pathways (The detailed analysis of the important candidates can be seen in Supplementary Material V). The methylation and mutation status of such genes have been confirmed to be abnormal during the progression of lung adenocarcinoma and similar solid tumors. Take FZD1 as an example, FZD1 is a functional gene on our list, which has been widely reported to be related to various tumor subtypes51,52. The methylation status of this gene has been associated with prostate cancer and age-associated diseases53,54. There are only a few reports of FZD1-associated mutations. However, it has been proven that the mutations of FZD-1 may be crucial for specific diseases including tumors, validating our prediction55,56. Considering that the gene expression is regulated by specific methylation process in the genome, this level, corresponding to the mRNA level diversity between the tumor tissue and the adjacent normal tissue, is associated with the first level (methylation diversity). Genes like MEN1, TCF3 and SHH, listed in Table 4, are all crucial genes that contribute to the initiation and progression of tumors on multiple levels (The detailed analysis of the important candidates can be seen in Supplementary Material V). TCF3 as we have mentioned above turns out to be confirmed to contribute to lung adenocarcinoma on methylation alteration49. What’s more, considering the expression regulation function of microRNAs, such identified microRNA-associated cancer driver may also contribute to tumor genesis on mRNA level. Some of the candidate genes have also been predicted to be related to both microRNA expression differentiation and mutation diversity of malignant and somatic cells. Interacting with microRNA-365 and microRNA-27b, the most important candidates for these two levels are listed in Table 5. COL1A2, SHC1, FKBP1A, TTN and NGF are all crucial cancer driver genes that contribute to lung adenocarcinoma in their respective ways (The detailed analysis of the important candidates can be seen in Supplementary Material V). The fifth group of genes (including PTCH1, SHH, ITGA2, ITGA5, GRB2, EP300 and SMC3, listed in Table 6) contribute to the progression of lung adenocarcinoma on at least the microRNA regulation and mRNA expression level (The detailed analysis of the important candidates can be seen in Supplementary Material V). As for the last set of genes, such genes ITGA2, ITGA5, NOTCH1, PXN and DYNLL1, listed in Table 7, contributes to tumors on both the mutation and mRNA levels (The detailed analysis of the important candidates can be seen in Supplementary Material V). All of our predicted genes that contribute to at least two levels have been confirmed to be real driver genes by recent publications

Analysis of candidate genes of high frequencies

In Section “Results”, six sets of candidate genes were obtained that were deemed to induce tumor initiation and progression on two levels. We took the union operation of these six sets and obtained 110 candidate genes. Among them, some genes occurred many times, meaning that they may drive tumor initiation and progression on multiple levels. Thus, the frequencies of 110 candidate genes were counted and listed in the Supplementary Material VI. Because there were totally six sets of candidate genes, six is the maximum value of frequencies for each candidate gene. This section gives a detailed discussion of the genes with frequencies greater than three (half of the maximum frequency), which are listed in Table 8. These candidate genes occurred in more than half of the candidate gene sets and have been reported and confirmed to participate in and contribute to the process of tumorigenesis. Here, their brief discussion is provided. Readers can found the detailed analyses in Supplementary Material VII.

Table 8. Frequencies of some core candidate genes.

Ensembl ID Gene symbol Description Frequency Pair of gene sets producing the candidate gene
ENSP00000332353 PTCH1 Patched 1 6 G1 and G2, G1 and G3, G1 and G4, G2 and G3, G2 and G4, G3 and G4
ENSP00000344456 CTNNB1 Catenin (Cadherin-Associated Protein), Beta 1, 88 kDa 6 G1 and G2, G1 and G3, G1 and G4, G2 and G3, G2 and G4, G3 and G4
ENSP00000357656 FYN FYN Proto-Oncogene, Src Family Tyrosine Kinase 6 G1 and G2, G1 and G3, G1 and G4, G2 and G3, G2 and G4, G3 and G4
ENSP00000162330 BCAR1 Breast Cancer Anti-Estrogen Resistance 1 5 G1 and G3, G1 and G4, G2 and G3, G2 and G4, G3 and G4
ENSP00000297261 SHH Sonic Hedgehog 5 G1 and G2, G1 and G3, G1 and G4, G2 and G4, G3 and G4
ENSP00000358525 NGF Nerve Growth Factor (Beta Polypeptide) 5 G1 and G2, G1 and G3, G2 and G3, G2 and G4, G3 and G4
ENSP00000361125 VEGFA Vascular Endothelial Growth Factor A 5 G1 and G3, G1 and G4, G2 and G3, G2 and G4, G3 and G4
ENSP00000387662 GCG Glucagon 5 G1 and G2, G1 and G3, G1 and G4, G2 and G4, G3 and G4
ENSP00000261769 CDH1 Cadherin 1, Type 1, E-Cadherin (Epithelial) 4 G1 and G3, G1 and G4, G2 and G3, G3 and G4
ENSP00000264657 STAT3 Signal Transducer And Activator Of Transcription 3 (Acute-Phase Response Factor) 4 G1 and G2, G1 and G3, G1 and G4, G2 and G4
ENSP00000277541 NOTCH1 Notch 1 4 G1 and G3, G2 and G3, G2 and G4, G3 and G4
ENSP00000296585 ITGA2 Integrin, Alpha 2 (CD49B, Alpha 2 Subunit Of VLA-2 Receptor) 4 G1 and G3, G2 and G3, G2 and G4, G3 and G4
ENSP00000312652 LEP Leptin 4 G1 and G2, G1 and G3, G1 and G4, G2 and G4
ENSP00000350941 SRC SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase 4 G1 and G3, G2 and G3, G2 and G4, G3 and G4
Open in a new tab

G1: A set containing 153 methylated CpG site genes; G2: A set containing 825 microRNA target genes; G3: A set containing 197 somatic mutation genes; G4: A set containing 1,373 mRNA genes.

Genes occurred in more than three gene sets have been analyzed. Three genes, PTCH1, CTNNB1, and FYN, have been predicted to contribute to the initiation and progression of lung adenocarcinoma in all the six gene sets. Such three genes have all been regarded as core functional cancer driver genes. Associated with proliferation and adhesion associated pathways such a PI-3K cascade, such three genes not only participate in the initiation and proliferation of the tumor , but regulate the metastasis processes as well57 (The detailed analysis of such genes can be seen in the Supplementary Material VII). As for the five genes (BCAR1, SHH, NGF, VEGFA, and GCG) that can be identified to be shared in five gene sets, they are also confirmed to be significant driver genes. Take BCAR1 as an example, such gene involves in crucial regulatory pathways like tyrosine kinase signaling pathways and further contribute to the survival, proliferation and invasion processes during tumorigenesis58 (The detailed analysis of such genes can be seen in the Supplementary Material VII). Quite more genes have been clustered in the group with the regulatory level frequency of four. Such genes regulate the abnormal pathways during the tumorigenesis processes such as the cell-cell adhesion regulation (CDH1), proliferation (STAT3, SRC), and chronic inflammatory reaction (LEP). All of such genes can be confirmed to be cancer driver genes by recent publications (The detailed analysis of such genes can be seen in the Supplementary Material VII).

As we have mentioned above, we identified a group of candidate cancer drivers that contribute to lung adenocarcinoma in multiple levels, which are all proved by recent literatures. Here, we may propose a new hypothesis for the initiation and progression of lung adenocarcinoma: the real core driver of lung adenocarcinoma (and maybe other cancers) may contribute to tumor genesis simultaneously on multiple levels. Considering the complicated regulatory system of human bodies, a single abnormal variation that contribute to the genomic alterations of a single level (e.g. mutations) may not be functional and significant enough to initiate the tumor genesis. The real core driver of cancer (lung adenocarcinoma) may contribute to tumor genesis on at least two levels to insure the initiation of malignant changes of normal cells. For example, the well-known typical core drivers for lung adenocarcinoma like EGFR all contribute to lung adenocarcinoma on multiple levels, though haven’t been identified and analyzed in the same publications19,59. All in all, based on our newly presented computational methods, we not only identified a group of novel cancer drivers for lung adenocarcinoma, but presented a new perspective for the underlying mechanisms of tumor genesis, providing a new sight into the initiation and progression of lung adenocarcinoma.

Conclusions

This contribution investigated the so-called cancer driver genes. A computational method was built to identify new potential candidate cancer driver genes. The analyses indicate that some of the obtained genes have the potential to drive tumorigenesis on multiple differentiation levels. It is hopeful that the findings presented in this study will promote the study of cancer driver genes and provide new insights into the investigation of tumor initiation. In this study, we used the protein information (protein-protein interaction) to investigate cancer driver genes. In future, we will consider adding some other information, such as microRNA related to cancer60, into our method, which may yield more useful information for the study of cancer driver gene.

Additional Information

How to cite this article: Chen, L. et al. Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach. Sci. Rep. 6, 29849; doi: 10.1038/srep29849 (2016).

Supplementary Material

Supplementary Information
srep29849-s1.pdf (1.4MB, pdf)

Acknowledgments

This study was supported by the National Natural Science Foundation of China (31371335), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12050201) and the Hi-Tech Research and Development Program of China (2014AA01A302).

Footnotes

Author Contributions T.H., M.Z., Y.J. and Y.-D.C. conceived the ideas and the study. L.C., Y.J. and Y.-D.C. performed the experiments. L.C., Y.-H.Z., T.H. and M.Z. analyzed the results. L.C. and Y.-H.Z. wrote the manuscript. All authors reviewed the manuscript.

References

  1. DeSantis C. E. et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64, 252–271, doi: 10.3322/caac.21235 (2014). [DOI] [PubMed] [Google Scholar]
  2. Conteduca V., Sansonno D., Russi S. & Dammacco F. Precancerous colorectal lesions (Review). International journal of oncology 43, 973–984, doi: 10.3892/ijo.2013.2041 (2013). [DOI] [PubMed] [Google Scholar]
  3. Tschaharganeh D. F. et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158, 579–592, doi: 10.1016/j.cell.2014.05.051 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Visani M. et al. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells. Int J Surg Pathol 21, 546–552, doi: 10.1177/1066896912475073 (2013). [DOI] [PubMed] [Google Scholar]
  5. Liang H. et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22, 2120–2129, doi: 10.1101/gr.137596.112 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Paziewska A. et al. DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy. British journal of cancer 111, 781–789, doi: 10.1038/bjc.2014.337 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cul’bová M. et al. Methylation of selected tumor-supressor genes in benign and malignant ovarian tumors. Ceska Gynekol 76, 274–279 (2011). [PubMed] [Google Scholar]
  8. Colangelo T. et al. MicroRNA-130b Promotes Tumor Development and Is Associated with Poor Prognosis in Colorectal Cancer. Neoplasia 15, 1086–1099, doi: 10.1593/neo.13998 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ota H. et al. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell 153, 575–589, doi: 10.1016/j.cell.2013.03.024 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Xiong J., Du Q. & Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene 29, 4980–4988, doi: 10.1038/onc.2010.241 (2010). [DOI] [PubMed] [Google Scholar]
  11. Xu J. M. et al. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. Journal of experimental & clinical cancer research : CR 33, 104, doi: 10.1186/s13046-014-0104-7 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Reitman Z. J., Pirozzi C. J. & Yan H. Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. Acta neuropathologica 126, 789–792, doi: 10.1007/s00401-013-1207-5 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gao L., Yang Q. H. & Xu R. K. [Melatonin inhibits the proliferation of pituitary prolactin-secreting tumor by suppressing the enhancer elements mutation of PRL gene in the rat]. Sheng Li Xue Bao 57, 319–327 (2005). [PubMed] [Google Scholar]
  14. Fredriksson N. J., Ny L., Nilsson J. A. & Larsson E. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat Genet 46, 1258–1263, doi: 10.1038/ng.3141 (2014). [DOI] [PubMed] [Google Scholar]
  15. Conti A. et al. Expression of the tumor necrosis factor receptor-associated factors 1 and 2 and regulation of the nuclear factor-kappaB antiapoptotic activity in human gliomas. J Neurosurg 103, 873–881, doi: 10.3171/jns.2005.103.5.0873 (2005). [DOI] [PubMed] [Google Scholar]
  16. Normanno N. & Cree I. A. Genomics driven-oncology: challenges and perspectives. BMC Cancer 15, 141, doi: 10.1186/s12885-015-1147-7 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Liang Y., Wakelee H. A. & Neal J. W. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non–Small-Cell Lung Cancer. Clin Lung Cancer 16, 366–373, doi: 10.1016/j.cllc.2014.12.009 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jin Y. et al. ROS1 gene rearrangement and copy number gain in non-small cell lung cancer. Virchows Arch 466, 45–52, doi: 10.1007/s00428-014-1679-2 (2015). [DOI] [PubMed] [Google Scholar]
  19. Zhang Y. et al. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. Sci Rep 4, 7163, doi: 10.1038/srep07163 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Qiu T., Guo H., Zhao H., Wang L. & Zhang Z. Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology. Sci Rep 5, 11317, doi: 10.1038/srep11317 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lee S. Y. et al. A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 26, 1142–1148, doi: 10.1093/annonc/mdv100 (2015). [DOI] [PubMed] [Google Scholar]
  22. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550, doi: 10.1038/nature13385 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Banerji S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405–409, doi: 10.1038/nature11154 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tusher V. G., Tibshirani R. & Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98, 5116–5121, doi: 10.1073/pnas.091062498 (2001). [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Griffiths-Jones S., Grocock R. J., van Dongen S., Bateman A. & Enright A. J. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34, D140–144, doi: 10.1093/nar/gkj112 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Friedman R. C., Farh K. K., Burge C. B. & Bartel D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19, 92–105, doi: 10.1101/gr.082701.108 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Betel D., Wilson M., Gabow A., Marks D. S. & Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 36, D149–153, doi: 10.1093/nar/gkm995 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sethupathy P., Corda B. & Hatzigeorgiou A. G. TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 12, 192–197, doi: 10.1261/rna.2239606 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Wang X. & El Naqa I. M. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 24, 325–332, doi: 10.1093/bioinformatics/btm595 (2008). [DOI] [PubMed] [Google Scholar]
  30. Krek A. et al. Combinatorial microRNA target predictions. Nat Genet 37, 495–500, doi: 10.1038/ng1536 (2005). [DOI] [PubMed] [Google Scholar]
  31. von Mering C. et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res 31, 258–261 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Franceschini A. et al. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic acids research 41, D808–D815 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Hu L. L. et al. Predicting functions of proteins in mouse based on weighted protein-protein interaction network and protein hybrid properties. PLoS ONE 6, e14556 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Chen L. et al. Application of the shortest path algorithm for the discovery of breast cancer related genes. Current Bioinformatics 11, 51–58 (2014). [Google Scholar]
  35. Gao P., Wang Q. P., Chen L. & Huang T. Prediction of Human Genes Regulatory Functions Based on Proteinprotein Interaction Network. Protein and Peptide Letters 19, 910–916 (2012). [DOI] [PubMed] [Google Scholar]
  36. Chen L., Chu C., Kong X., Huang G. & Huang T. A Hybrid Computational Method for the Discovery of Novel Reproduction-Related Genes. PLoS ONE 10, e0117090 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Jiang Y. et al. Identifying Gastric Cancer Related Genes Using the Shortest Path Algorithm and Protein-Protein Interaction Network. BioMed Research International 2014, 371397 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Chen L., Chu C., Kong X., Huang T. & Cai Y. Discovery of New Candidate Genes Related to Brain Development Using Protein Interaction Information. PLoS ONE 10, e0118003 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Chen L. et al. Mining for novel tumor suppressor genes using a shortest path approach. Journal of Biomolecular Structure and Dynamics 34, 664–675, doi: 10.1080/07391102.2015.1042915 (2016). [DOI] [PubMed] [Google Scholar]
  40. Zhang J., Yang J., Huang T., Shu Y. & Chen L. Identification of novel proliferative diabetic retinopathy related genes on protein-protein interaction network. Neurocomputing (2016). [Google Scholar]
  41. Ng K. L., Ciou J. S. & Huang C. H. Prediction of protein functions based on function-function correlation relations. Comput Biol Med 40, 300–305, doi: DOI 10.1016/j.compbiomed.2010.01.001 (2010). [DOI] [PubMed] [Google Scholar]
  42. Li B. Q., Huang T., Liu L., Cai Y. D. & Chou K. C. Identification of Colorectal Cancer Related Genes with mRMR and Shortest Path in Protein-Protein Interaction Network. PLoS One 7, e33393, doi: 10.1371/journal.pone.0033393 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Jiang M. et al. Identification of hepatocellular carcinoma related genes with k-th shortest paths in a protein-protein interaction network. Mol Biosyst 9, 2720–2728, doi: 10.1039/c3mb70089e (2013). [DOI] [PubMed] [Google Scholar]
  44. Gormen T. H., Leiserson C. E., Rivest R. L. & Stein C. (MIT press Cambridge, MA, 1990).
  45. Kitsak M. et al. Betweenness centrality of fractal and nonfractal scale-free model networks and tests on real networks. Physical review. E, Statistical, nonlinear, and soft matter physics 75, 056115 (2007). [DOI] [PubMed] [Google Scholar]
  46. Cukierski W. J. & Foran D. J. Using Betweenness Centrality to Identify Manifold Shortcuts. Proc IEEE Int Conf Data Min 2008, 949–958 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Gao Y. F. et al. Predicting Metabolic Pathways of Small Molecules and Enzymes Based on Interaction Information of Chemicals and Proteins. PLoS ONE 7, e45944 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Sharan R., Ulitsky I. & Shamir R. Network-based prediction of protein function. Mol Syst Biol 3, 88 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Barnie P. A. et al. CpG-oligodeoxynucleotides suppress the proliferation of A549 lung adenocarcinoma cells via toll-like receptor 9 signaling and upregulation of Runt-related transcription factor 3 expression. Biomed Rep 2, 374–377, doi: 10.3892/br.2014.257 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Hu J. et al. MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells. Tumour Biol 35, 8953–8961, doi: 10.1007/s13277-014-2158-8 (2014). [DOI] [PubMed] [Google Scholar]
  51. Zhang H. et al. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/beta-catenin pathway. Cancer letters 323, 106–113, doi: 10.1016/j.canlet.2012.03.039 (2012). [DOI] [PubMed] [Google Scholar]
  52. Hung T. H. et al. FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells. Int J Biochem Cell Biol 53, 55–65, doi: 10.1016/j.biocel.2014.04.011 (2014). [DOI] [PubMed] [Google Scholar]
  53. Devaney J. M. et al. Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia. Prostate Cancer P D 16, 292–300, doi: 10.1038/pcan.2013.58 (2014). [DOI] [PubMed] [Google Scholar]
  54. Salpea P. et al. Postnatal development- and age-related changes in DNA-methylation patterns in the human genome. Nucleic Acids Research 40, 6477–6494, doi: 10.1093/nar/gks312 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Katoh M. Molecular cloning and characterization of WRCH2 on human chromosome 15q15. International journal of oncology 20, 977–982 (2002). [PubMed] [Google Scholar]
  56. Kaykas A. et al. Mutant Frizzled 4 associated with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization. Nature Cell Biology 6, 52–U13, doi: 10.1038/ncb1081 (2004). [DOI] [PubMed] [Google Scholar]
  57. Elias D. & Ditzel H. J. Fyn is an important molecule in cancer pathogenesis and drug resistance. Pharmacological research : the official journal of the Italian Pharmacological Society 100, 250–254, doi: 10.1016/j.phrs.2015.08.010 (2015). [DOI] [PubMed] [Google Scholar]
  58. Grebenchtchikov N. et al. Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue. Clin Chem 50, 1356–1363, doi: 10.1373/clinchem.2003.029868 (2004). [DOI] [PubMed] [Google Scholar]
  59. Schneeberger V. E. et al. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget 6, 6191–6202, doi: 10.18632/oncotarget.3356 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Zeng X., Zhang X. & Zou Q. Integrative approaches for predicting microRNA function and prioritizing disease-related microRNA using biological interaction networks. Briefings in bioinformatics 17, 193–203, doi: 10.1093/bib/bbv033 (2016). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep29849-s1.pdf (1.4MB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES